company background image
QURE logo

uniQure NasdaqGS:QURE Stock Report

Last Price

US$6.31

Market Cap

US$312.6m

7D

-2.0%

1Y

9.5%

Updated

30 Oct, 2024

Data

Company Financials +

QURE Stock Overview

Develops treatments for patients suffering from rare and other devastating diseases.

QURE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

uniQure N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for uniQure
Historical stock prices
Current Share PriceUS$6.31
52 Week HighUS$11.35
52 Week LowUS$3.73
Beta0.94
11 Month Change27.89%
3 Month Change-15.71%
1 Year Change9.46%
33 Year Change-82.44%
5 Year Change-87.57%
Change since IPO-56.84%

Recent News & Updates

uniQure's Yellow Flags: Early-Stage Gene Therapies Amid Restructuring

Oct 21

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

Aug 06

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 03
uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Recent updates

uniQure's Yellow Flags: Early-Stage Gene Therapies Amid Restructuring

Oct 21

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

Aug 06

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 03
uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts

Jul 09

Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

Mar 03
Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

uniQure: The Valuation Got More Attractive

Feb 01

Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding

Jan 17
Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding

A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)

Dec 15
A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)

Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)

Aug 27
Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)

Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be

Aug 06
Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be

Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money

Aug 02
Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money

uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough

Jul 02
uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough

Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher

Jun 28
Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

May 14
uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

Apr 11
Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat

Mar 01
News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat

Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?

Dec 09
Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?

uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion

Sep 21

uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch

Aug 30

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

Aug 14
uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy

Aug 08

These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

Jun 08
These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

May 04
uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications

Apr 08

We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings

Mar 04
We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings

The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically

Feb 27
The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically

Is uniQure (NASDAQ:QURE) A Risky Investment?

Feb 23
Is uniQure (NASDAQ:QURE) A Risky Investment?

uniQure: Betting On Hemophilia-B Cure

Jan 18

Shareholder Returns

QUREUS BiotechsUS Market
7D-2.0%-0.2%-0.09%
1Y9.5%27.0%38.6%

Return vs Industry: QURE underperformed the US Biotechs industry which returned 27% over the past year.

Return vs Market: QURE underperformed the US Market which returned 38.6% over the past year.

Price Volatility

Is QURE's price volatile compared to industry and market?
QURE volatility
QURE Average Weekly Movement11.1%
Biotechs Industry Average Movement9.7%
Market Average Movement6.1%
10% most volatile stocks in US Market15.2%
10% least volatile stocks in US Market3.0%

Stable Share Price: QURE's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: QURE's weekly volatility has decreased from 16% to 11% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1998480Matt Kapustawww.uniqure.com

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer’s disease; and AMT-210 that is in preclinical trial to treat Parkinson’s disease.

uniQure N.V. Fundamentals Summary

How do uniQure's earnings and revenue compare to its market cap?
QURE fundamental statistics
Market capUS$312.64m
Earnings (TTM)-US$284.69m
Revenue (TTM)US$27.71m

11.1x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
QURE income statement (TTM)
RevenueUS$27.71m
Cost of RevenueUS$195.83m
Gross Profit-US$168.12m
Other ExpensesUS$116.57m
Earnings-US$284.69m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-5.85
Gross Margin-606.80%
Net Profit Margin-1,027.52%
Debt/Equity Ratio533.9%

How did QURE perform over the long term?

See historical performance and comparison